Lipoxin A4and its analogue suppress the tumor growth of transplanted H22 in mice: The role of antiangiogenesis

Molecular Cancer Therapeutics

Volumn 9, Issue 8, 2010, Pages 2164-2174

  Chen, Ying ^a   Hao, Hua ^a   He, Songqing ^b   Cai, Lei ^a   Li, Yongsheng ^a   Hu, Shunze ^a   Ye, Duyun ^a   Hoidal, John ^c   Wu, Ping ^a,c   Chen, Xiaoping ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BML 111; CD34 ANTIBODY; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LIPOXIN A; UNCLASSIFIED DRUG; VASCULOTROPIN; 5(S),6(R) 7 TRIHYDROXYHEPTANOIC ACID, METHYL ESTER; 5(S),6(R)-7-TRIHYDROXYHEPTANOIC ACID, METHYL ESTER; HEPTANOIC ACID DERIVATIVE; LIPOXIN; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; APOPTOSIS; ARTICLE; CANCER GRAFT; CANCER INHIBITION; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VASCULARIZATION; ANIMAL; BIOSYNTHESIS; CANCER TRANSPLANTATION; CELL PROLIFERATION; DISEASE COURSE; DRUG EFFECT; DRUG SCREENING; HUMAN; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; DRUG SCREENING ASSAYS, ANTITUMOR; HEPTANOIC ACIDS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIPOXINS; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77955500501     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0173     Document Type: Article

References (50)

1. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002;2:795-803.
2. Rossler J, Taylor M, Geoerger B, et al. Angiogenesis as a target in neuroblastoma. Eur J Cancer 2008;44:1645-56.
3. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-45.
4. Serhan CN. Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL): a jungle of cell-cell interactions or a therapeutic opportunity? Prostaglandins 1997;53:107-37.
5. Serhan CN. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol 2007;25:101-37.
6. Planaguma A, Kazani S, Marigowda G, et al. Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma. Am J Respir Crit Care Med 2008;178:574-82.
7. Medeiros R, Rodrigues GB, Figueiredo CP, et al. Molecular mechanisms of topical anti-inflammatory effects of lipoxin A(4) in endotoxininduced uveitis. Mol Pharmacol 2008;74:154-61.
8. Kieran NE, Maderna P, Godson C. Lipoxins:potential anti-inflammatory, proresolution, and antifibrotic mediators in renal disease. Kidney Int 2004;65:1145-54. (Pubitemid 38406952)
9. Zhou XY, Wu P, Zhang L, et al. Effects of lipoxin A(4) on lipopolysaccharide induced proliferation and reactive oxygen species production in RAW264.7 macrophages through modulation of G-CSF secretion. Inflamm Res 2007;56:324-33.
10. Jin SW, Zhang L, Lian QQ, et al. Posttreatment with aspirin-triggered lipoxin A4 analog attenuates lipopolysaccharide-induced acute lung injury in mice: the role of heme oxygenase-1. Anesth Analg 2007;104:369-77.
11. Li YS, Wu P, Zhou XY, et al. Formyl-peptide receptor like 1: a potent mediator of the Ca2+ release-activated Ca2+ current ICRAC. Arch Biochem Biophys 2008;478:110-8.
12. Fierro IM, Kutok JL, Serhan CN. Novel lipid mediator regulators of endothelial cell proliferation and migration: aspirin-triggered-15R-lipoxin A(4) and lipoxin A(4). J Pharmacol Exp Ther 2002; 300:385-92.
13. Cezar-de-Mello PF, Vieira AM, Nascimento-Silva V, Villela CG, Barja-Fidalgo C, Fierro IM. ATL-1, an analogue of aspirin-triggered lipoxin A4, is a potent inhibitor of several steps in angiogenesis induced by vascular endothelial growth factor. Br J Pharmacol 2008;153:956-65.
14. Bannenberg GL, Aliberti J, Hong S, Sher A, Serhan C. Exogenous pathogen and plant 15-lipoxygenase initiate endogenous lipoxin A4 biosynthesis. J Exp Med 2004;199:515-23. (Pubitemid 38233835)
15. Machado FS, Aliberti J. Impact of lipoxin-mediated regulation on immune response to infectious disease. Immunol Res 2006;35:209-18.
16. Hunter CA, Yu D, Gee M, et al. Cutting edge: systemic inhibition of angiogenesis underlies resistance to tumors during acute toxoplasmosis. J Immunol 2001;166:5878-81.
17. Kim JO, Jung SS, Kim SY, et al. Inhibition of Lewis lung carcinoma growth by Toxoplasma gondii through induction of Th1 immune responses and inhibition of angiogenesis. J Korean Med Sci 2007;22 Suppl:S38-46.
18. Petasis NA, Akritopoulou-Zanze I, Fokin VV, et al. Design, synthesis and bioactions of novel stable mimetics of lipoxins and aspirintriggered lipoxins. Prostaglandins Leukot Essent Fatty Acids 2005; 73:301-21. (Pubitemid 41253490)
19. Lee TH, Lympany P, Crea AE, Spur BW. Inhibition of leukotriene B4-induced neutrophil migration by lipoxin A4: structure-function relationships. Biochem Biophys Res Commun 1991;180:1416-21.
20. Zhang L, Wan J, Li H, et al. Protective effects of BML-111, a lipoxin A (4) receptor agonist, on carbon tetrachloride-induced liver injury in mice. Hepatol Res 2007;37:948-56.
21. L'Azou B, Fernandez P, Bareille R, et al. In vitro endothelial cell susceptibility to xenobiotics: comparison of three cell types. Cell Biol Toxicol 2005;21:127-37.
22. Zhang J, Wang X, Lu H. Amifostine increases cure rate of cisplatin on ascites hepatoma 22 via selectively protecting renal thioredoxin reductase. Cancer Lett 2008;260:127-36.
23. Pagel JM, Hedin N, Drouet L, et al. Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy. Blood 2008;111:2261-8.
24. Shen FZ, Wang J, Liang J, Mu K, Hou JY, Wang YT. Low-dose metronomic chemotherapy with cisplatin: Can it suppress angiogenesis in H22 hepatocarcinoma cells? Int J Exp Pathol 2010;91:10-6.
25. Yogo Y, Fujishima S, Inoue T, et al. Macrophage derived chemokine (CCL22), thymus and activation-regulated chemokine (CCL17), and CCR4 in idiopathic pulmonary fibrosis. Respir Res 2009;10:80.
26. Jin JJ, Kim HD, Maxwell JA, Li L, Fukuchi K. Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease. J Neuroinflammation 2008;5:23. (Pubitemid 351877817)
27. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010;29:625-34.
28. Griguer CE, Oliva CR, Kelley EE, Giles GI, Lancaster JR, Jr., Gillespie GY. Xanthine oxidase-dependent regulation of hypoxia-inducible factor in cancer cells. Cancer Res 2006;66:2257-63.
29. Fabregat I. Dysregulation of apoptosis in hepatocellular carcinoma cells. World J Gastroenterol 2009;15:513-20.
30. Leng J, Han C, Demetris AJ, Michalopoulos GK, Wu T. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology 2003;38:756-68.
31. Kern MA, Schubert D, Sahi D, et al. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology 2002;36:885-94.
32. Kaseb AO, Hanbali A, Cotant M, Hassan MM, Wollner I, Philip PA. Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature. Cancer 2009;115:4895-906.
33. Claria J, Planaguma A. Liver: the formation and actions of aspirin-triggered lipoxins. Prostaglandins Leukot Essent Fatty Acids 2005; 73:277-82. (Pubitemid 41253487)
34. Fernandez A, Udagawa T, Schwesinger C, et al. Angiogenic potential of prostate carcinoma cells overexpressing bcl-2. J Natl Cancer Inst 2001;93:208-13.
35. Kallergi G, Markomanolaki H, Giannoukaraki V, et al. Hypoxiainducible factor-1α and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients. Breast Cancer Res 2009;11:R84.
36. Rankin EB, Giaccia AJ. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 2008;15:678-85.
37. Sooriakumaran P, Kaba R. Angiogenesis and the tumour hypoxia response in prostate cancer: a review. Int J Surg 2005;3:61-7. (Pubitemid 41095569)
38. Caltana L, Merelli A, Lazarowski A, Brusco A. Neuronal and glial alterations due to focal cortical hypoxia induced by direct cobalt chloride (CoCl2) brain injection. Neurotox Res 2009;15:348-58.
39. Lin CY, Lin CJ, Chen KH, Wu JC, Huang SH, Wang SM. Macrophage activation increases the invasive properties of hepatoma cells by destabilization of the adherens junction. FEBS Lett 2006;580:3042-50.
40. Macpherson GR, Ng SS, Forbes SL, et al. Anti-angiogenic activity of human endostatin is HIF-1-independent in vitro and sensitive to timing of treatment in a human saphenous vein assay. Mol Cancer Ther 2003;2:845-54.
41. Baker N, O'Meara SJ, Scannell M, Maderna P, Godson C. Lipoxin A4: anti-inflammatory and anti-angiogenic impact on endothelial cells. J Immunol 2009;182:3819-26.
42. Cezar-de-Mello PF, Nascimento-Silva V, Villela CG, Fierro IM. Aspirin-triggered Lipoxin A4 inhibition of VEGF-induced endothelial cell migration involves actin polymerization and focal adhesion assembly. Oncogene 2006;25:122-9.
43. Jin Y, Arita M, Zhang Q, et al. Anti-angiogenesis effect of the novel anti-inflammatory and proresolving lipid mediators. Invest Ophthalmol Vis Sci 2009;50:4743-52.
44. Maddox JF, Hachicha M, Takano T, Petasis NA, Fokin VV, Serhan CN. Lipoxin A4 stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein-linked lipoxin A4 receptor. J Biol Chem 1997;272:6972-8.
45. Siveen KS, Kuttan G. Role of macrophages in tumour progression. Immunol Lett 2009;123:97-102.
46. Luo Y, Zhou H, Krueger J, et al. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest 2006; 116:2132-41. (Pubitemid 44162322)
47. Lee S, Chen TT, Barber CL, et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 2007;130:691-703. (Pubitemid 47268059)
48. Claria J, Lee MH, Serhan CN. Aspirin-triggered lipoxins (15-epi-LX) are generated by the human lung adenocarcinoma cell line (A549)-neutrophil interactions and are potent inhibitors of cell proliferation. Mol Med 1996;2:583-96.
49. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-39.
50. Greenberg JI, Cheresh DA. VEGF as an inhibitor of tumor vessel maturation: implications for cancer therapy. Expert Opin Biol Ther 2009; 9:1347-56.